Identification of EGFR and KRAS mutations in Chinese patients with esophageal squamous cell carcinoma

Diseases of the Esophagus

Volumn 24, Issue 5, 2011, Pages 374-380

  Liu, Q W ^a   Fu, J H ^a   Luo, K J ^a   Yang, H X ^a   Wang, J Y ^a   Hu, Y ^a   Yang, H ^a   Bella, E ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Epidermal growth factor receptor; Esophageal squamous cell carcinoma; KRAS; Mutation

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; FORMALDEHYDE; K RAS PROTEIN; PARAFFIN; CODON; EGFR PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; PROTEIN P21;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER STAGING; CELL DIFFERENTIATION; CHINESE; CODON; CONTROLLED STUDY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; EXON; FEMALE; GENDER; GENE AMPLIFICATION; GENE DELETION; GENE MUTATION; GENE SEQUENCE; GENETIC CORRELATION; GROUPS BY AGE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIRSTEN SARCOMA ONCOVIRUS; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; ONCOGENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; SMOKING; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; ESOPHAGUS TUMOR; GENETICS; MIDDLE AGED; MUTATION; PATHOLOGY; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, SQUAMOUS CELL; CHINA; CODON; ESOPHAGEAL NEOPLASMS; EXONS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS P21(RAS); RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 79960580978     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2010.01155.x     Document Type: Article

References (38)

1. Kamangar F, Dores G M, Anderson W F. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24: 2137-50.
2. Lu S, Lin P, Wang G, Luo X, Wu M. Comprehensive prevention and treatment for esophageal cancer. Chin Med J (Engl) 1999; 112: 918-23.
3. Wakeling A E, Guy S P, Woodburn J R etal. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2002; 62: 5749-54.
4. Fukuoka M, Yano S, Giaccone G etal. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 2003; 21: 2237-46.
5. Kris M G, Natale R B, Herbst R S etal. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290: 2149-58.
6. Lynch T J, Bell D W, Sordella R etal. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-39.
7. Paez J G, Janne P A, Lee J C etal. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-500.
8. Pao W, Miller V, Zakowski M etal. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004; 101: 13306-11.
9. Chou T Y, Chiu C H, Li L H etal. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Clin Cancer Res 2005; 11: 3750-7.
10. Han S W, Kim T Y, Hwang P G etal. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2005; 23: 2493-501.
11. Finberg K E, Sequist L V, Joshi V A etal. Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features. J Mol Diagn 2007; 9: 320-6.
12. Kwak E L, Jankowski J, Thayer S P etal. Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clin Cancer Res 2006; 12 (Pt 1): 4283-7.
13. Sudo T, Mimori K, Nagahara H etal. Identification of EGFR mutations in esophageal cancer. Eur J Surg Oncol 2007; 33: 44-8.
14. Guo M, Liu S, Lu F. Gefitinib-sensitizing mutations in esophageal carcinoma. N Engl J Med 2006; 354: 2193-4.
15. Hanawa M, Suzuki S, Dobashi Y etal. EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus. Int J Cancer 2006; 118: 1173-80.
16. Janmaat M L, Gallegos-Ruiz M I, Rodriguez J A etal. Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. J Clin Oncol 2006; 24: 1612-19.
17. Puhringer-Oppermann F A, Stein H J, Sarbia M. Lack of EGFR gene mutations in exons 19 and 21 in esophageal (Barrett's) adenocarcinomas. Dis Esophagus 2007; 20: 9-11.
18. Meltzer S J, Mane S M, Wood P K etal. Activation of c-Ki-ras in human gastrointestinal dysplasias determined by direct sequencing of polymerase chain reaction products. Cancer Res 1990; 50: 3627-30.
19. Casson A G, Wilson S M, McCart J A etal. ras mutation and expression of the ras-regulated genes osteopontin and cathepsin L in human esophageal cancer. Int J Cancer 1997; 72: 739-45.
20. Trautmann B, Wittekind C, Strobel D etal. K-ras point mutations are rare events in premalignant forms of Barrett's oesophagus. Eur J Gastroenterol Hepatol 1996; 8: 799-804.
21. Sommerer F, Vieth M, Markwarth A etal. Mutations of BRAF and KRAS2 in the development of Barrett's adenocarcinoma. Oncogene 2004; 23: 554-8.
22. Lord R V, O'Grady R, Sheehan C, Field A F, Ward R L. K-ras codon 12 mutations in Barrett's oesophagus and adenocarcinomas of the oesophagus and oesophagogastric junction. J Gastroenterol Hepatol 2000; 15: 730-6.
23. Arber N, Shapira I, Ratan J etal. Activation of c-K-ras mutations in human gastrointestinal tumors. Gastroenterology 2000; 118: 1045-50.
24. Lyronis I D, Baritaki S, Bizakis I, Krambovitis E, Spandidos j D A. K-ras mutation, HPV infection and smoking or alcohol abuse positively correlate with esophageal squamous carcinoma. Pathol Oncol Res 2008; 14: 267-73.
25. Victor T, Du Toit R, Jordaan A M, Bester A J, van Helden P D. No evidence for point mutations in codons 12, 13, and 61 of the ras gene in a high-incidence area for esophageal and gastric cancers. Cancer Res 1990; 50: 4911-14.
26. Hara F, Aoe M, Doihara H etal. Antitumor effect of gefitinib ('Iressa') on esophageal squamous cell carcinoma cell lines in vitro and in vivo. Cancer Lett 2005; 226: 37-47.
27. Dragovich T, McCoy S, Fenoglio-Preiser C M etal. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol 2006; 24: 4922-7.
28. Ferry D R, Anderson M, Beddard K etal. A phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response. Clin Cancer Res 2007; 13: 5869-75.
29. Enzinger P C, Mayer R J. Esophageal cancer. N Engl J Med 2003; 349: 2241-52.
30. Thatcher N, Chang A, Parikh P etal. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366: 1527-37.
31. Park S H, Ha S Y, Lee J I etal. Epidermal growth factor receptor mutations and the clinical outcome in male smokers with squamous cell carcinoma of lung. J Korean Med Sci 2009; 24: 448-52.
32. Na I I, Kang H J, Cho S Y etal. EGFR mutations and human papillomavirus in squamous cell carcinoma of tongue and tonsil. Eur J Cancer 2007; 43: 520-6.
33. Horiike A, Kimura H, Nishio K etal. Detection of epidermal growth factor receptor mutation in transbronchial needle aspirates of non-small cell lung cancer. Chest 2007; 131: 1628-34.
34. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004; 64: 8919-23.
35. Rodenhuis S, Slebos R J, Boot A J etal. Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. Cancer Res 1988; 48: 5738-41.
36. Sasaki M, Sugio K, Sasazuki T. K-ras activation in colorectal tumors from patients with familial polyposis coli. Cancer 1990; 65: 2576-9.
37. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988; 53: 549-54.
38. Shigematsu H, Lin L, Takahashi T etal. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005; 97: 339-46.